Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

about

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

Item

http://www.wikidata.org/entity/Q58776981

description

im Juni 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 June 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@en

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@nl

type

Item

label

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@en

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@nl

prefLabel

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@en

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@nl

P1476

Sustained efficacy and detaile ...... hase 3 results from RESONATE-2

@en

P2093

Alessandra Tedeschi

http://www.w3.org/2001/XMLSchema#string

Carol Moreno

http://www.w3.org/2001/XMLSchema#string

Carolyn Owen

http://www.w3.org/2001/XMLSchema#string

Cathy Zhou

http://www.w3.org/2001/XMLSchema#string

Danelle James

http://www.w3.org/2001/XMLSchema#string

David Simpson

http://www.w3.org/2001/XMLSchema#string

Fritz Offner

http://www.w3.org/2001/XMLSchema#string

Helen McCarthy

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Jianyong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Genomic aberrations and survival in chronic lymphocytic leukemia

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

P304

1502-1510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2018.192328

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Ghia

Nancy L Bartlett

Sebastian Grosicki

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29880603

http://www.w3.org/2001/XMLSchema#string

P921

hematology

leukemia

P932

6119145

http://www.w3.org/2001/XMLSchema#string